Ondine Biomedical Inc
LSE:OBI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Ondine Biomedical Inc
Research & Development
Ondine Biomedical Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Ondine Biomedical Inc
LSE:OBI
|
Research & Development
-CA$9.2m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Profound Medical Corp
TSX:PRN
|
Research & Development
-$20.6m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-18%
|
|
|
Theralase Technologies Inc
XTSX:TLT
|
Research & Development
-CA$2.6m
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
2%
|
|
|
MedMira Inc
XTSX:MIR
|
Research & Development
-CA$585.4k
|
CAGR 3-Years
-9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
5%
|
|
|
Aurora Spine Corp
XTSX:ASG
|
Research & Development
-$764.5k
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-25%
|
|
|
Conavi Medical Corp
XTSX:CNVI
|
Research & Development
-$13m
|
CAGR 3-Years
34%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
10%
|
|
Ondine Biomedical Inc
Glance View
Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.
See Also
What is Ondine Biomedical Inc's Research & Development?
Research & Development
-9.2m
CAD
Based on the financial report for Dec 31, 2024, Ondine Biomedical Inc's Research & Development amounts to -9.2m CAD.
What is Ondine Biomedical Inc's Research & Development growth rate?
Research & Development CAGR 3Y
-23%
Over the last year, the Research & Development growth was -79%. The average annual Research & Development growth rates for Ondine Biomedical Inc have been -23% over the past three years .
